Your guide to health and prenatal genetics
Mother hold baby

Assess your personalised prenatal risks, choose screening tests, and find nearby maternity clinics

Serenity (verifi) Test

Producer: Illumina
Launch date: Mar 2012
Description: NIPT provided by Illumina, a genetic sequencing leader
Gestation week: 10+

Common Aneuploidies


  • 22q11 (Di George syndrome)*
  • 15q11 (Angelman syndrome)*
  • 15q11 (Prader Willi syndrome)*
  • 1p36 deletion syndrome*
  • 5p (Cri-du-chat syndrome)*
  • 4p16.3 (Wolf-Hirschhorn syndrome)*

Sex chromosomes aneuploidies

  • Monosomy X (X0) (Turner syndrome)*
  • XXY (Klinefelter syndrome)*
  • XXX (Triple X)*
  • XYY (Jacob syndrome)*


  • Gender*

* - optional conditions

Reporting time: 3-5 working days + additional sample delivery time
Price: from £399
Singletons: natural:   Yes
Singletons: IVF (self egg):   Yes
Singletons: IVF (donor egg):   Yes
Twins:   Yes
Fetal fraction:   No
Tests performed: > 86 000
Limitations: can not be used for: - earlier pregnancy (gestation) week than indicated; - multiple pregnancies (more than two baby); - previously unrecognised vanishing twin; - previously undiagnosed (and normaly benign) maternal chromosomal disorders; - chromosomal mosaicism (maternal or placental); - tumour disorders of the mother; - if following treatments received in the last 3 months: blood transfusion, bone marrow transplantation, radiation therapy; - cancer diagnosis
Sample requirements: 1 tube (provided in kit) with 7-10 ml of the maternal blood
Location: Verinata Health, Inc. an Illumina Company, Redwood City, CA (USA); CAP-accredited and CLIA-certified laboratory; available through selected partners. In the UK verifi® test is mostly known as Serenity™ (performed by Genesis Genetics, London, UK)
Technology: Whole genome NGS
Type: Centralised test as a service
Methodology: Total cfDNA from maternal blood is sequenced by massively parallel or next generation sequencing (MPS/NGS) whole approach. Proprietary bioinformatic algorithm (SAFeR) is then used to count the fetal and maternal cfDNA fragments specific to the chromosomes, calculate the ratio and hence provide a risk of an affected pregnancy.


Promotional & Educational Media:

For Expecting parents:

Patients counseling Video:

Information brochures: 

Sample reports:

  • Verifi (Serenity) sample report


Information last updated 11/12/15